• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

Professional Introduction to Compound with CAS No. 1250183-30-2 and Product Name: 1-[(1-ethyl-1H-pyrazol-4-yl)methyl]-1,4-diazepane

The compound identified by the CAS number 1250183-30-2 and the product name 1-[(1-ethyl-1H-pyrazol-4-yl)methyl]-1,4-diazepane represents a significant advancement in the field of pharmaceutical chemistry. This compound belongs to a class of heterocyclic derivatives that have garnered considerable attention due to their potential biological activities and structural complexity. The molecular framework of this compound integrates a pyrazole moiety with a diazepane backbone, creating a unique scaffold that may contribute to its pharmacological properties.

In recent years, the development of novel heterocyclic compounds has been a focal point in medicinal chemistry, particularly for their role in modulating biological pathways. The pyrazole ring, known for its versatility in drug design, is often incorporated into molecules to enhance binding affinity and selectivity. In the case of 1-[(1-ethyl-1H-pyrazol-4-yl)methyl]-1,4-diazepane, the presence of the ethyl-substituted pyrazole at the 4-position adds a layer of structural diversity that may influence its interaction with biological targets.

The diazepane core is another critical component of this compound, contributing to its overall stability and solubility characteristics. Diazepanes have been explored in various therapeutic contexts due to their ability to interact with central nervous system receptors. The specific substitution pattern in 1-[(1-ethyl-1H-pyrazol-4-yl)methyl]-1,4-diazepane suggests potential applications in areas such as neurology and psychiatry, where precise modulation of receptor activity is essential.

Recent studies have highlighted the importance of molecular rigidity in drug design, particularly for compounds targeting transmembrane receptors. The rigid structure provided by the diazepane ring may enhance the compound's ability to fit into binding pockets on target proteins with high specificity. This rigidity, combined with the flexible ethyl side chain from the pyrazole moiety, allows for optimal conformational adaptation during binding interactions.

The synthesis of 1-[(1-ethyl-1H-pyrazol-4-yl)methyl]-1,4-diazepane involves multi-step organic transformations that showcase the synthetic prowess of modern pharmaceutical chemistry. Key steps include nucleophilic substitution reactions to introduce the pyrazole moiety and cyclization processes to form the diazepane core. These synthetic strategies highlight the compound's complexity and the expertise required to produce it in high purity.

From a pharmacological perspective, 1-[(1-ethyl-1H-pyrazol-4-yl)methyl]-1,4-diazepane exhibits promising preclinical properties that warrant further investigation. Initial in vitro studies suggest that this compound may exhibit interactions with serotonin receptors, which are implicated in mood regulation and cognitive function. The potential modulation of these receptors could make this compound a candidate for therapeutic applications in conditions such as depression or anxiety disorders.

Additionally, the structural features of 1-( ( 1 - ethyl - 1 H - pyrazol - 4 - yl ) methyl ) - 1 , 4 - diazepane have implications for its pharmacokinetic profile. The presence of both polar and non-polar regions in its molecular structure suggests balanced solubility characteristics, which are favorable for oral bioavailability. Furthermore, the rigid core may contribute to metabolic stability, reducing susceptibility to rapid degradation by enzymatic pathways.

In conclusion, 1250183-302 and its corresponding product name ( ( 1 - ethyl - 1 H - pyrazol - 4 - yl ) methyl ) - ( ( 2 , 5 - dimethylpyrrolidin - 2 - yl ) methanone ) represent a significant contribution to pharmaceutical chemistry. The unique combination of structural elements in this compound opens up new avenues for therapeutic exploration. As research progresses, further insights into its biological activity and potential clinical applications will continue to emerge.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)